Related Experiment Video
Updated: Nov 4, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.7K
Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia
Journal of Postgraduate Medicine
|May 28, 2021
Summary
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, fatal heart condition. Cardiac sympathetic denervation (CSD) effectively managed a patient with CPVT when other treatments failed, preventing syncope and arrhythmias.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, life-threatening inherited arrhythmogenic disorder.
- Diagnosis and management of CPVT present significant clinical challenges.
- Recurrent exertional syncope and ventricular ectopy are key clinical indicators.
Observation:
- A 21-year-old male presented with recurrent exertional syncope and multifocal ventricular ectopy.
- CPVT diagnosis was established clinically, despite the absence of some classic findings.
- Standard treatments including lifestyle changes and medications were ineffective.
Findings:
- The patient underwent cardiac sympathetic denervation (CSD) as a therapeutic intervention.
- CSD demonstrated significant effectiveness in managing the patient's condition.
- No exertional symptoms or syncope recurrence were observed during a 1-year follow-up.
Implications:
- This case supports the efficacy of CSD as a treatment option for refractory CPVT.
- Cardiac sympathetic denervation offers a viable therapeutic strategy for managing this challenging arrhythmia.
- Further evidence strengthens the role of CSD in the clinical management of CPVT.
More Related Videos
07:50Location, Dissection, and Analysis of the Murine Stellate Ganglion
Published on: December 22, 2020
11.5K
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
15.0K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
640
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
640
01:30Cardiomyopathy II: Dilated Cardiomyopathy
114
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
114
01:22Heart Failure Drugs: β-Blockers
539
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
539
01:29Cardiomyopathy V: Interprofessional Care
96
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
96
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
113
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
113
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K